Metagenomi Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Metagenomi Therapeutics, Inc. (MGX) had Debt Securities, Available-for-sale, Amortized Cost of $118.98 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $118.98M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $138.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $159.54M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $182.70M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $118.98M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $138.40M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $159.54M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $182.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $203.57M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $224.25M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $246.38M 10-K · filed 2026-03-05 |
| 2024-09-30 | $271.68M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $298.79M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $325.86M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $267.89M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |